Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Paul Y. Goldberg Insider Profile
4 Followers
Paul Y. Goldberg, SVP, Clinical Development at Xenon, holds 6.00K shares in Xenon (Ticker: XENE). Most recently, Paul Y. Goldberg Sold $30,491 shares of Xenon on Sep 24, 2015 for an estimated value of 276.15K.
Paul Y. Goldberg has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Paul Y. Goldberg's holdings
Insider Roles
SVP, Clinical Development
Roles that Paul Y. Goldberg holds in companies
Most Profitable Insider Trade
The most profitable trade made by Paul Y. Goldberg
Paul Y. Goldberg's Trading History
List of latest transactions for each holding click on a transaction to see Paul Y. Goldberg's performance on stock
You May Also Like
Paul Y. Goldberg insider profile FAQ
What is the percentage of profitable transactions made by Paul Y. Goldberg?
The percentage of profitable transactions made by Paul Y. Goldberg is ―.
What is the average return per transaction made by Paul Y. Goldberg?
The average return per transaction made by Paul Y. Goldberg is ―.
What stocks does Paul Y. Goldberg hold?
Paul Y. Goldberg holds: XENE stocks.
What was Paul Y. Goldberg’s latest transaction?
Paul Y. Goldberg latest transaction was an Informative Sell of $276.15K.
What was Paul Y. Goldberg's most profitable transaction?
Paul Y. Goldberg’s most profitable transaction was an Informative Sell of XENE stock on September 24, 2015. The return on the trade was 8.70%.
What is Paul Y. Goldberg's role in Xenon?
Paul Y. Goldberg's role in Xenon is SVP, Clinical Development.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.